U.S. markets closed

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.8500+0.0200 (+2.41%)
At close: 3:59PM EST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.8300
Open0.8400
Bid0.8300 x 0
Ask0.8500 x 0
Day's Range0.8300 - 0.8700
52 Week Range0.2500 - 1.8000
Volume11,536
Avg. Volume80,668
Market Cap119.963M
Beta (5Y Monthly)-0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateMar 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board
      ACCESSWIRE

      Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board

      RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr.

    • Helix Biopharma Corp. Reports Voting Results
      ACCESSWIRE

      Helix Biopharma Corp. Reports Voting Results

      RICHMOND HILL, ON / ACCESSWIRE / January 28, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021 (the "Meeting").

    • Helix Biopharma Corp. Responds to Market Activity
      ACCESSWIRE

      Helix Biopharma Corp. Responds to Market Activity

      RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.